Ernexa Therapeutics (ERNA) Set to Post Quarterly Earnings on Friday

Ernexa Therapeutics (NASDAQ:ERNA) is expected to release its resultson Friday, November 6th. Analysts expect the company to announce earnings of ($3.84) per share for the quarter.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.10). On average, analysts expect Ernexa Therapeutics to post ($18.02) EPS for the current fiscal year and ($1.86) EPS for the next fiscal year.

Ernexa Therapeutics Trading Up 3.6%

Shares of ERNA stock opened at $2.02 on Wednesday. The company has a 50 day moving average price of $3.19 and a 200-day moving average price of $7.33. Ernexa Therapeutics has a 52 week low of $1.84 and a 52 week high of $47.25.

Analyst Ratings Changes

ERNA has been the topic of a number of recent research reports. Wall Street Zen cut Ernexa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Thursday, October 15th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $30.00.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.